Evaxion Biotech to Host Q1 2021 Corporate Update Conference Call & Webcast on May 13
Evaxion Biotech (NASDAQ: EVAX) will present its Q1 2021 financial results on May 13, 2021. CEO Lars Wegner and CFO Glenn Vraniak will lead an earnings call at 8:30 a.m. EDT. Dial-in numbers: US: 877-407-0792, International: +1-201-689-8263, Conference ID: 13718732. An audio webcast will be available on Evaxion's website. The company develops AI-driven immunotherapies targeting cancer and infectious diseases, with a pipeline including three patient-specific cancer treatments currently in Phase 1/2a trials.
- None.
- None.
COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will present its first-quarter 2021 financial results on May 13.
Lars Wegner, CEO of Evaxion, and Glenn Vraniak, CFO, will host an earnings call on May 13 at 8.30 a.m. EDT.
To dial-in for the conference call, please use the following details:
US: 877-407-0792
International: +1-201-689-8263
Conference ID: 13718732
Alternatively to access the audio webcast, please visit the events page of Evaxion’s website at:
https://evaxion-biotech.com/news-and-events/events/default.aspx
A webcast replay will be available on the Evaxion website approximately two hours after the event.
About Evaxion
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase 1/2a clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.
| For more information | ||
| Evaxion | LifeSci Advisors LLC | |
| Glenn S. Vraniak | Mary-Ann Chang | |
| Chief Financial Officer | Managing Director | |
| gvr@evaxion-biotech.com | mchang@lifesciadvisors.com | |
| +1 (513) 476-2669 | +44 7483 284 853 | |
Source: Evaxion Biotech
Forward-looking statement
This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company’s business operations and financial condition.
Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s prospectus filed on February 5, 2021 and the Company’s current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
FAQ
When will Evaxion Biotech announce its Q1 financial results?
What time is the earnings call for Evaxion Biotech?
What is the conference call ID for Evaxion Biotech's earnings call?
How can I access the audio webcast of Evaxion Biotech's earnings call?
What is Evaxion Biotech's focus in biotechnology?
